Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease states ranging from simple steatosis (a build-up of fat in the liver) to the more end stage of the disease characterised by fibrosis, cirrhosis and potentially even cancer (termed HCC). Due to the ongoing obesity epidemic, NAFLD has become the disease of the Western world. It is already the biggest cause of HCC in the Western world and by 2030 it is predicted to be the main cause of liver transplants. Despite this, we still do not have any therapeutic options for patients and while weight loss can be effective early in disease, this is not sufficient at the more end stages of the disease spectrum. Immune cells such as macrophages and dendritic cells have been proposed to play crucial roles in driving the progression of NAFLD, but we still do not fully understand what roles they play. This is because in recent years it has become clear that there are many different subsets of these cells in the liver, likely performing different functions. In the past these cells have been studied collectively, however now it's clear that we need to split these up and study them individually to fully understand their unique contributions to NAFLD progression. This is the goal of this project. In MyeFattyLiver, we aim to investigate the different subsets of these cells in both NAFLD models and patient liver samples. We want to understand which subsets are there and most importantly what each subset does. This is crucial because only once we study the individual contributions of these cells can we begin to develop novel therapeutic strategies for patients with NAFLD.